Published Date: 02 Mar 2023
Many doctors have accused hospitals and large hospitals of opposing quality care and promoting violence. Others disagree.
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.
Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’
After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.
FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years
Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial
Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children
1.
Liquid Biopsy for Colorectal Cancer Screening Might Not Be Ready for Prime Time.
2.
Dual imaging capsule captures 3D tissue and blood vessel changes for early esophageal cancer diagnosis
3.
Research finds low uptake of supportive care at the end-of-life for patients with advanced cancer
4.
New drug combination shows good results in patients with HPV-negative head and neck cancer
5.
Q&A: When will individuals be able to receive customized cancer vaccines?
1.
Revolutionizing Lung Transplantation: The Promise of Donor-Specific Blood Transfusion
2.
Recent Advances in Paroxysmal Nocturnal Hemoglobinuria Research: Promising Therapies on the Horizon
3.
The Unseen Threat: Uncovering the Risks of Pancoast Tumor
4.
Immunotherapy Breakthroughs: Transforming Cancer Care Across All Oncology Fields
5.
Cardiotoxicity Beyond Anthracyclines: Redefining Risk in the Cardio-Oncology Era
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
3.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation